4FR Stock Overview
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Faron Pharmaceuticals Oy Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£2.37 |
52 Week High | UK£4.45 |
52 Week Low | UK£1.35 |
Beta | -0.13 |
1 Month Change | 62.77% |
3 Month Change | -24.52% |
1 Year Change | -31.60% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -32.67% |
Recent News & Updates
Recent updates
Shareholder Returns
4FR | DE Biotechs | DE Market | |
---|---|---|---|
7D | 28.8% | -1.8% | 1.1% |
1Y | -31.6% | -24.9% | 6.5% |
Return vs Industry: 4FR underperformed the German Biotechs industry which returned -25.4% over the past year.
Return vs Market: 4FR underperformed the German Market which returned 5.9% over the past year.
Price Volatility
4FR volatility | |
---|---|
4FR Average Weekly Movement | 21.5% |
Biotechs Industry Average Movement | 5.2% |
Market Average Movement | 5.0% |
10% most volatile stocks in DE Market | 10.4% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4FR's share price has been volatile over the past 3 months.
Volatility Over Time: 4FR's weekly volatility has increased from 12% to 21% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 34 | Juho Jalkanen | www.faron.com |
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company’s lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company is also developing bexmarilimab, which is in phase 2 clinical trial for indications of solid tumors; and in phase 1 clinical trial for indications of acute myeloid leukemia and myelodysplastic syndromes.
Faron Pharmaceuticals Oy Fundamentals Summary
4FR fundamental statistics | |
---|---|
Market cap | €188.50m |
Earnings (TTM) | -€30.94m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.1x
P/E RatioIs 4FR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4FR income statement (TTM) | |
---|---|
Revenue | €0 |
Cost of Revenue | €0 |
Gross Profit | €0 |
Other Expenses | €30.94m |
Earnings | -€30.94m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 27, 2024
Earnings per share (EPS) | -0.43 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -85.1% |
How did 4FR perform over the long term?
See historical performance and comparison